Anne Gadomski

TL;DR: This guideline is a revision of the clinical practice guideline, “Diagnosis and Management of Bronchiolitis,” published by the American Academy of Pediatrics in 2006, and indicates level of evidence, benefit-harm relationship, and level of recommendation.

TL;DR: The updated recommendations in this policy statement reflect new information regarding the seasonality of RSV circulation, palivizumab pharmacokinetics, the changing incidence of bronchiolitis hospitalizations, the effect of gestational age and other risk factors on RSV hospitalization rates, the mortality of children hospitalized with RSV infection, the effects of prophylaxis on wheezing, and palivZumab-resistant RSV isolates.

TL;DR: Bronchodilators such as albuterol or salbutamol do not improve oxygen saturation, do not reduce hospital admission after outpatient treatment, doNot shorten the duration of hospitalization and do not shorten the time to resolution of illness at home.

TL;DR: Bronchodilators produce modest short-term improvement in clinical features of mild or moderately severe bronchiolitis, and the results were similar, but the data varied more.

TL;DR: The best individual finding for ruling out pneumonia is the absence of tachypnea, and studies are needed to assess the value of clinical findings when they are used together.